Osteomyelofibrose ist eine Knochemarkerkrankung bei der es zu einer übermäßigen Fibrosierung des Knochenmarkes kommt. Das Knochenmark wird von fibrotischem Narbengewebe verdrängt. Die Erkrankung kann durch somatische Mutationen im JAK2-Gen hervorgerufen werden.
1. |
Kralovics R et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. |
2. |
Cassinat B et al. (2014) Interferon alfa therapy in CALR-mutated essential thrombocythemia. |
3. |
Passamonti F et al. (2014) JAK inhibitor in CALR-mutant myelofibrosis. |
4. |
Cazzola M et al. (2014) JAK inhibitor in CALR-mutant myelofibrosis. |
5. |
Jutzi JS et al. (2013) MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. |
6. |
Kaufmann KB et al. (2012) A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. |
7. |
Pardanani AD et al. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. |
8. |
Pikman Y et al. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. |
9. |
Bonduel M et al. (1998) Familial idiopathic myelofibrosis and multiple hemangiomas. |
10. |
Sieff CA et al. (1980) Familial myelofibrosis. |
11. |
Delhommeau F et al. (2009) Mutation in TET2 in myeloid cancers. |
12. |
Arranz L et al. (2014) Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. |
13. |
Méndez-Ferrer S et al. (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. |
14. |
Méndez-Ferrer S et al. (2008) Haematopoietic stem cell release is regulated by circadian oscillations. |
15. |
Baxter EJ et al. () Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. |
16. |
Orphanet article Orphanet ID 824 |
17. |
OMIM.ORG article Omim 254450 |
18. |
Wikipedia Artikel Wikipedia DE (Osteomyelofibrose) |